Hubei Chen Xiaoping Development

Hubei Chen Xiaoping Science and Technology Development is a clinical-stage biotechnology company headquartered in Wuhan, China, specializing in the development of malaria-based cancer immunotherapies. The company was founded by Dr. Chen Xiaoping to commercialize research on the use of Plasmodium parasites to stimulate the human immune system against advanced solid tumors. Their primary therapeutic approach involves a controlled malaria infection that triggers a systemic inflammatory response, activating natural killer cells and T cells to target malignant growths. Currently, the company is advancing its lead program through Phase 1 and Phase 2 clinical trials, focusing on patients with late-stage lung cancer and other refractory solid tumors. This novel modality aims to provide an alternative for patients who have failed standard-of-care treatments like chemotherapy or checkpoint inhibitors.